Revolution Medicines’ RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted US FDA Orphan Drug Designation in Pancreatic Cancer

Revolution Medicines, Inc. announced that the US FDA has granted Orphan Drug Designation to daraxonrasib, the company’s RAS(ON) multi-selective inhibitor, for the treatment of pancreatic cancer.